Dimebon

Phase 3Small molecule

Pfizer

Dimebon is one of 29 small molecule programs targeting Huntington disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Huntington DiseaseActive, not recruiting

Huntington DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Huntington Disease

#DrugCompanyPhaseTrials

Epidiolex

Actigall

Dojolvi

Tasigna

AAzurity Pharmaceuticals

Approved

—5

Rilutek

AAzurity Pharmaceuticals

Glucophage

Tricor

Risperdal

Haldol

Lithobid

SSolvay Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alzheimer's Disease4 trials

An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease

Terminated· Pfizer logo

Pfizer·Phase 3·NCT01066546·5 enrolled

Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

Terminated·MMedivation, Inc.·Phase 2·NCT00704782·50 enrolled

An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00939783·649 enrolled

Show 1 more trial

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

Completed·MMedivation, Inc.·Phase 3·NCT00675623·598 enrolled

Mild to Moderate Alzheimer's Disease3 trials

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

Completed· Pfizer logo

Pfizer·Phase 3·NCT00838110·742 enrolled

Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease

Completed·MMedivation, Inc.·Phase 2·NCT00377715·183 enrolled

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

Completed·MMedivation, Inc.·Phase 3·NCT00829374·1,003 enrolled

Phase 13 trials

A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan

Completed· Pfizer logo

Pfizer·Phase 1·NCT00788047·14 enrolled

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00825084·45 enrolled

A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT00907322·12 enrolled

Moderate to Severe Alzheimer's Disease2 trials

A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00912288·86 enrolled

A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

Terminated·MMedivation, Inc.·Phase 3·NCT00954590·89 enrolled

Tics2 trials

A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

Completed· Pfizer logo

Pfizer·Phase 1·NCT00988624·20 enrolled

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

Completed· Pfizer logo

Pfizer·Phase 1·NCT00931073·24 enrolled

9 more indications

Randomized2 trials

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00827034·14 enrolled

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

Completed· Pfizer logo

Pfizer·Phase 1·NCT00824590·20 enrolled

Huntington's Disease2 trials

Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

Completed·MMedivation, Inc.·Phase 1/2·NCT00387270·9 enrolled

A Study of the Novel Drug Dimebon in Patients With Huntington's Disease

Completed·MMedivation, Inc.·Phase 2·NCT00497159·91 enrolled

Huntington disease2 trials

An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

Terminated·MMedivation, Inc.·Phase 3·NCT01085266·362 enrolled

A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

Completed·MMedivation, Inc.·Phase 3·NCT00920946·403 enrolled

Mebo1 trial

Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil

Completed·MMedivation, Inc.·Phase 1·NCT00829816·46 enrolled

Absorption1 trial

A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

Completed· Pfizer logo

Pfizer·Phase 1·NCT00990613·19 enrolled

Interaction1 trial

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00831506·12 enrolled

Hepatic Impairment1 trial

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

Completed· Pfizer logo

Pfizer·Phase 1·NCT00831532·23 enrolled

Abuse Potential1 trial

A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

Completed· Pfizer logo

Pfizer·Phase 1·NCT00975481·36 enrolled

Unspecified1 trial

An Extension of the CONCERT Protocol (DIM18)

Terminated·MMedivation, Inc.·Phase 3·NCT01152216·672 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Dimebon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dimebon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dimebon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Dimebon

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alzheimer's Disease4 trials

Mild to Moderate Alzheimer's Disease3 trials

Phase 13 trials

Moderate to Severe Alzheimer's Disease2 trials

Tics2 trials

Randomized2 trials

Huntington's Disease2 trials

Huntington disease2 trials

Mebo1 trial

Absorption1 trial

Interaction1 trial

Hepatic Impairment1 trial

Abuse Potential1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News